share_log

Cybin | 6-K/A: Report of foreign private issuer (related to financial reporting)

SEC announcement ·  Jun 28 00:43
Summary by Futu AI
Cybin Inc., a clinical-stage biopharmaceutical company, has filed an amended report with the SEC for June 2024, correcting an inadvertent incorporation by reference in its original Form 6-K and updating the date of a news release in the Exhibit Index. The company, which focuses on developing psychedelic-based treatments for mental health disorders, reported significant progress in its fiscal year 2024. Cybin received FDA Breakthrough Therapy Designation for CYB003, a psilocybin analog for Major Depressive Disorder, and completed site selection for a Phase 3 multinational study expected to begin in summer 2024. Cybin also initiated a Phase 2 study for CYB004, targeting Generalized Anxiety Disorder. Financially, Cybin reported a cash total of C$209 million as of March 31, 2024, and closed an oversubscribed private placement of U.S.$150 million. Despite these advancements, the company experienced an increased net loss of C$78 million for the year, compared to C$47 million the previous year. The company's CEO, Doug Drysdale, expressed optimism about the upcoming Phase 3 study and the potential impact of their treatments on mental health disorders.
Cybin Inc., a clinical-stage biopharmaceutical company, has filed an amended report with the SEC for June 2024, correcting an inadvertent incorporation by reference in its original Form 6-K and updating the date of a news release in the Exhibit Index. The company, which focuses on developing psychedelic-based treatments for mental health disorders, reported significant progress in its fiscal year 2024. Cybin received FDA Breakthrough Therapy Designation for CYB003, a psilocybin analog for Major Depressive Disorder, and completed site selection for a Phase 3 multinational study expected to begin in summer 2024. Cybin also initiated a Phase 2 study for CYB004, targeting Generalized Anxiety Disorder. Financially, Cybin reported a cash total of C$209 million as of March 31, 2024, and closed an oversubscribed private placement of U.S.$150 million. Despite these advancements, the company experienced an increased net loss of C$78 million for the year, compared to C$47 million the previous year. The company's CEO, Doug Drysdale, expressed optimism about the upcoming Phase 3 study and the potential impact of their treatments on mental health disorders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.